KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Sales (2016 - 2025)

Historic Return on Sales for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to 0.49%.

  • Halozyme Therapeutics' Return on Sales rose 200.0% to 0.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.48%, marking a year-over-year increase of 600.0%. This contributed to the annual value of 0.44% for FY2024, which is 1000.0% up from last year.
  • Halozyme Therapeutics' Return on Sales amounted to 0.49% in Q3 2025, which was up 200.0% from 0.51% recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Return on Sales registered a high of 1.87% during Q3 2021, and its lowest value of 0.15% during Q2 2022.
  • For the 5-year period, Halozyme Therapeutics' Return on Sales averaged around 0.49%, with its median value being 0.4% (2024).
  • Per our database at Business Quant, Halozyme Therapeutics' Return on Sales soared by 13200bps in 2021 and then crashed by -15700bps in 2022.
  • Halozyme Therapeutics' Return on Sales (Quarter) stood at 0.65% in 2021, then plummeted by -51bps to 0.32% in 2022, then increased by 17bps to 0.37% in 2023, then rose by 24bps to 0.46% in 2024, then increased by 8bps to 0.49% in 2025.
  • Its Return on Sales was 0.49% in Q3 2025, compared to 0.51% in Q2 2025 and 0.45% in Q1 2025.